Correlation Between Caribou Biosciences and Blueprint Medicines
Can any of the company-specific risk be diversified away by investing in both Caribou Biosciences and Blueprint Medicines at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Caribou Biosciences and Blueprint Medicines into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Caribou Biosciences and Blueprint Medicines Corp, you can compare the effects of market volatilities on Caribou Biosciences and Blueprint Medicines and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Caribou Biosciences with a short position of Blueprint Medicines. Check out your portfolio center. Please also check ongoing floating volatility patterns of Caribou Biosciences and Blueprint Medicines.
Diversification Opportunities for Caribou Biosciences and Blueprint Medicines
0.7 | Correlation Coefficient |
Poor diversification
The 3 months correlation between Caribou and Blueprint is 0.7. Overlapping area represents the amount of risk that can be diversified away by holding Caribou Biosciences and Blueprint Medicines Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Blueprint Medicines Corp and Caribou Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Caribou Biosciences are associated (or correlated) with Blueprint Medicines. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Blueprint Medicines Corp has no effect on the direction of Caribou Biosciences i.e., Caribou Biosciences and Blueprint Medicines go up and down completely randomly.
Pair Corralation between Caribou Biosciences and Blueprint Medicines
Given the investment horizon of 90 days Caribou Biosciences is expected to under-perform the Blueprint Medicines. In addition to that, Caribou Biosciences is 1.74 times more volatile than Blueprint Medicines Corp. It trades about -0.02 of its total potential returns per unit of risk. Blueprint Medicines Corp is currently generating about 0.05 per unit of volatility. If you would invest 4,797 in Blueprint Medicines Corp on October 15, 2024 and sell it today you would earn a total of 3,946 from holding Blueprint Medicines Corp or generate 82.26% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Significant |
Accuracy | 100.0% |
Values | Daily Returns |
Caribou Biosciences vs. Blueprint Medicines Corp
Performance |
Timeline |
Caribou Biosciences |
Blueprint Medicines Corp |
Caribou Biosciences and Blueprint Medicines Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Caribou Biosciences and Blueprint Medicines
The main advantage of trading using opposite Caribou Biosciences and Blueprint Medicines positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Caribou Biosciences position performs unexpectedly, Blueprint Medicines can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Blueprint Medicines will offset losses from the drop in Blueprint Medicines' long position.Caribou Biosciences vs. Intellia Therapeutics | Caribou Biosciences vs. Editas Medicine | Caribou Biosciences vs. Crispr Therapeutics AG | Caribou Biosciences vs. Verve Therapeutics |
Blueprint Medicines vs. Terns Pharmaceuticals | Blueprint Medicines vs. Amylyx Pharmaceuticals | Blueprint Medicines vs. Acumen Pharmaceuticals | Blueprint Medicines vs. Inozyme Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Complementary Tools
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |